Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors

被引：10

作者：

Bewersdorf, Jan Philipp ^{[1
]}

Shallis, Rory M. ^{[2
,3
]}

Derkach, Andriy ^{[4
]}

Goldberg, Aaron D. ^{[1
]}

Stein, Anthony ^{[5
]}

Stein, Eytan M. ^{[1
]}

Marcucci, Guido ^{[5
]}

Zeidan, Amer M. ^{[2
,3
]}

Shimony, Shai ^{[6
]}

DeAngelo, Daniel J. ^{[6
]}

Stone, Richard M. ^{[6
]}

Aldoss, Ibrahim ^{[5
]}

Ball, Brian J. ^{[5
]}

Stahl, Maximilian ^{[6
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[2] Yale Univ, New Haven, CT USA

[3] Yale Canc Ctr, New Haven, CT USA

[4] Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidemiol, 1275 York Ave, New York, NY 10021 USA

[5] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[6] Dana Farber Canc Inst, Div Leukemia, Dept Med Oncol, Boston, MA 02115 USA

来源：

LEUKEMIA & LYMPHOMA | 2023年 / 64卷 / 01期

基金：

美国国家卫生研究院;

关键词：

Acute myeloid leukemia; AML; targeted agents; venetoclax; outcomes; AZACITIDINE; COMBINATION;

D O I：

10.1080/10428194.2022.2136952

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

FLT3, IDH1 and IDH2 inhibitors as well as venetoclax in combination with hypomethylating agents or low-dose cytarabine have expanded treatment options for patients with acute myeloid leukemia (AML). However, little data exist on the efficacy of venetoclax-based therapies in AML patients previously treated with FLT3 or IDH1/2 inhibitors. In this multicenter, retrospective cohort study, we included 44 patients who received venetoclax-based therapy after FLT3, IDH1 or IDH2 inhibitors. The overall response rate (ORR; composite of complete remission [CR]/CR with incomplete count recovery, partial remission, and morphologic leukemia free state) was 56.8% (18.2% CR) and a median overall survival of 9.2 months. While 6 out of 7 patients with IDH1 mutations who had previously been treated with ivosidenib responded to venetoclax-based therapy, FLT3-ITD mutations were associated with a lower response rate. Our data suggest that venetoclax can be an effective salvage therapy in patients previously treated with IDH1/2 or FLT3 inhibitors.

引用

页码：188 / 196

页数：9

共 18 条

[11] Harnessing the benefits of available targeted therapies in acute myeloid leukaemia [J].

Kantarjian, Hagop ;

Short, Nicholas J. ;

DiNardo, Courtney ;

Stein, Eytan M. ;

Daver, Naval ;

Perl, Alexander E. ;

Wang, Eunice S. ;

Wei, Andrew ;

Tallman, Martin .

LANCET HAEMATOLOGY, 2021, 8 (12) :E922-E933

[12] Acute myeloid leukemia: current progress and future directions [J].

Kantarjian, Hagop ;

Kadia, Tapan ;

DiNardo, Courtney ;

Daver, Naval ;

Borthakur, Gautam ;

Jabbour, Elias ;

Garcia-Manero, Guillermo ;

Konopleva, Marina ;

Ravandi, Farhad .

BLOOD CANCER JOURNAL, 2021, 11 (02)

[13] Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia [J].

Montesinos, Pau ;

Recher, Christian ;

Vives, Susana ;

Zarzycka, Ewa ;

Wang, Jianxiang ;

Bertani, Giambattista ;

Heuser, Michael ;

Calado, Rodrigo T. ;

Schuh, Andre C. ;

Yeh, Su-Peng ;

Daigle, Scott R. ;

Hui, Jianan ;

Pandya, Shuchi S. ;

Gianolio, Diego A. ;

de Botton, Stephane ;

Dohner, Hartmut .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (16) :1519-1531

[14] Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML [J].

Perl, A. E. ;

Martinelli, G. ;

Cortes, J. E. ;

Neubauer, A. ;

Berman, E. ;

Paolini, S. ;

Montesinos, P. ;

Baer, M. R. ;

Larson, R. A. ;

Ustun, C. ;

Fabbiano, F. ;

Erba, H. P. ;

Di Stasi, A. ;

Stuart, R. ;

Olin, R. ;

Kasner, M. ;

Ciceri, F. ;

Chou, W-C ;

Podoltsev, N. ;

Recher, C. ;

Yokoyama, H. ;

Hosono, N. ;

Yoon, S-S ;

Lee, J-H ;

Pardee, T. ;

Fathi, A. T. ;

Liu, C. ;

Hasabou, N. ;

Liu, X. ;

Bahceci, E. ;

Levis, M. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (18) :1728-1740

[15] Impact of Venetoclax and Azacitidine in Treatment-Naive Patients with Acute Myeloid Leukemia and IDH1/2 Mutations [J].

Pollyea, Daniel A. ;

DiNardo, Courtney D. ;

Arellano, Martha L. ;

Pigneux, Arnaud ;

Fiedler, Walter ;

Konopleva, Marina ;

Rizzieri, David A. ;

Smith, B. Douglas ;

Shinagawa, Atsushi ;

Lemoli, Roberto M. ;

Dail, Monique ;

Duan, Yinghui ;

Chyla, Brenda ;

Potluri, Jalaja ;

Miller, Catherine L. ;

Kantarjian, Hagop M. .

CLINICAL CANCER RESEARCH, 2022, 28 (13) :2753-2761

[16] A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study [J].

Short, Nicholas J. ;

DiNardo, Courtney D. ;

Daver, Naval ;

Nguyen, Daniel ;

Yilmaz, Musa ;

Kadia, Tapan M. ;

Garcia-Manero, Guillermo ;

Issa, Ghayas C. ;

Huang, Xuelin ;

Qiao, Wei ;

Sasaki, Koji ;

Montalban-Bravo, Guillermo ;

Chien, Kelly S. ;

Borthakur, Gautam ;

Delumpa, Ricardo ;

Milton, Anna ;

Pierce, Sherry A. ;

Jabbour, Elias J. ;

Konopleva, Marina ;

Kantarjian, Hagop ;

Ravandi, Farhad .

BLOOD, 2021, 138

[17] Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML [J].

Stahl, Maximilian ;

Menghrajani, Kamal ;

Derkach, Andriy ;

Chan, Alexander ;

Xiao, Wenbin ;

Glass, Jacob ;

King, Amber C. ;

Daniyan, Anthony F. ;

Famulare, Christopher ;

Cuello, Bernadette M. ;

Horvat, Troy Z. ;

Abdel-Wahab, Omar ;

Levine, Ross L. ;

Viny, Aaron D. ;

Stein, Eytan M. ;

Cai, Sheng F. ;

Roshal, Mikhail ;

Tallman, Martin S. ;

Goldberg, Aaron D. .

BLOOD ADVANCES, 2021, 5 (05) :1552-1564

[18] Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia [J].

Stein, Eytan M. ;

DiNardo, Courtney D. ;

Pollyea, Daniel A. ;

Fathi, Amir T. ;

Roboz, Gail J. ;

Altman, Jessica K. ;

Stone, Richard M. ;

DeAngelo, Daniel J. ;

Levine, Ross L. ;

Flinn, Ian W. ;

Kantarjian, Hagop M. ;

Collins, Robert ;

Patel, Manish R. ;

Frankel, Arthur E. ;

Stein, Anthony ;

Sekeres, Mikkael A. ;

Swords, Ronan T. ;

Medeiros, Bruno C. ;

Willekens, Christophe ;

Vyas, Paresh ;

Tosolini, Alessandra ;

Xu, Qiang ;

Knight, Robert D. ;

Yen, Katharine E. ;

Agresta, Sam ;

de Botton, Stephane ;

Tallman, Martin S. .

BLOOD, 2017, 130 (06) :722-731

← 1 2 →